Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/18/2020 02/19/2020 02/20/2020 02/21/2020 02/24/2020 Date
149.14(c) 148.94(c) 148.37(c) 149.93(c) 145.91(c) Last
7 231 010 6 115 220 7 465 047 7 776 835 10 429 135 Volume
-0.66% -0.13% -0.38% +1.05% -2.68% Change
More quotes
Financials (USD)
Sales 2020 85 861 M
EBIT 2020 27 634 M
Net income 2020 19 976 M
Finance 2020 322 M
Yield 2020 2,75%
Sales 2021 90 138 M
EBIT 2021 30 022 M
Net income 2021 22 921 M
Finance 2021 3 988 M
Yield 2021 2,87%
P/E ratio 2020 19,8x
P/E ratio 2021 16,7x
EV / Sales2020 4,47x
EV / Sales2021 4,22x
Capitalization 384 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (51.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
02/24Ex-dividend day for
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
04:38pJ&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24JOHNSON & JOHNSON : Ex-dividend day for
FA
02/19JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health and Hum..
AQ
02/19JOHNSON & JOHNSON : to Participate in Cowen 40th Annual Health Care Conference
AQ
02/18JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATION..
AQ
02/18Sanofi to Work on Coronavirus Vaccine
DJ
02/18JOHNSON & JOHNSON : Expands Partnership With HHS to Find Coronavirus Treatment
DJ
02/18JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health & Human..
PU
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/14Carney says business must come clean quickly on climate
RE
02/13BY THE NUMBERS : 5 Ways Johnson & Johnson Is Helping Support Coronavirus Relief ..
AQ
02/12JOHNSON & JOHNSON : to Participate in the 9th Annual SVB Leerink Global Healthca..
PR
02/11JOHNSON & JOHNSON : J&J's Janssen to Work With HHS on Accelerating Coronavirus V..
DJ
02/11JOHNSON & JOHNSON : Announces Collaboration with U.S. Department of Health & Hum..
PR
02/07JOHNSON & JOHNSON : Hit with $750M Punitive Damages Verdict for Failing to Warn ..
PR
More news
News in other languages on JOHNSON & JOHNSON
02/24JOHNSON & JOHNSON : Ex-dividend day for
02/19Virgin Galactic n'en finit plus de s'envoler en Bourse
02/14J&J : nouvelles données positives pour l'Ustekinumab
02/09Coronavirus und die Börsen
02/07'BABY POWDER'-KLAGEN : Weitere hohe Strafe gegen Johnson & Johnson
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
04:38pJ&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
04:11pGrain Futures Fall as Coronavirus Spreads
DJ
12:20pNOVARTIS : FDA, EMA Accept Filings for Ofatumumab in Relapsing Multiple Sclerosi..
DJ
12:13pLONZA : France's Sanofi to carve out active drug ingredients business
RE
10:39aSANOFI : to Create Pharmaceutical Ingredients Leader With Eyes to Spinoff
DJ
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 160,00  $
Last Close Price 146,03  $
Spread / Highest target 18,5%
Spread / Average Target 9,57%
Spread / Lowest Target -8,92%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.78%395 024
ROCHE HOLDING AG10.13%300 195
NOVARTIS2.72%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.83%197 679
NOVO NORDISK AS13.46%149 779